Dynavax Acquired by Sanofi for $2.2 Billion at $15.50 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Fool
- Acquisition Deal: Sanofi has proposed to acquire Dynavax for $15.50 per share in cash, valuing the deal at approximately $2.2 billion, which represents a 39% premium over Tuesday's closing price, with the transaction expected to close in Q1 2026, significantly enhancing returns for Dynavax investors.
- Market Reaction: Following the announcement of the acquisition, Dynavax's stock surged over 38% to $15.38, reflecting positive market sentiment towards the deal and indicating investor confidence in the company's future prospects.
- Product Integration: The merger will combine Dynavax's adult hepatitis B vaccine with Sanofi's extensive global development and commercial distribution network, aiming to address unmet healthcare needs, particularly for nearly 100 million adults in the U.S. who have not yet been vaccinated against hepatitis B.
- Vaccine Development Outlook: Dynavax's shingles vaccine candidate is currently in early clinical development, and with Sanofi's resources and expertise, it is expected to accelerate its market launch, further strengthening the company's competitive position in the vaccine sector.
DVAX
$15.38+Infinity%1D
Analyst Views on DVAX
Wall Street analysts forecast DVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVAX is 21.00 USD with a low forecast of 11.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 11.130
Low
11.00
Averages
21.00
High
32.00
Current: 11.130
Low
11.00
Averages
21.00
High
32.00
About DVAX
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
